# Qlaris Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qlaris-bio

- Industry: Biotechnology
- Headquarters: Dedham, US
- Website: www.qlaris.bio
- Total disclosed funding: $32M
- Latest round: Series B (Apr 11, 2024)
- Investors on record: 5

## About

Based in Massachusetts, US, and co-founded by Thurein Htoo (CEO) and Barbara Wirostko (CMO) in 2019, Qlaris Bio, Inc. operates as a biotechnology company that engages in developing topical therapeutic drugs. In April 2024 the firm raised USD 24.03 million in series B funding co-led by investors Canaan Partners and New Leaf Venture Partners, with participation from other investors abrdn, Correlation Ventures, and Mayo Clinic Ventures.

The clinical-stage biotech company’s product is QLS-111, a therapy designed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP). With a vasodilatory mechanism of action, QLS-111 has the potential to address critical unmet needs in conditions such as Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and rare diseases like Sturge-Weber Syndrome. 

The company plans to utilize the April 2024 funding to support its research and development for ophthalmic treatment.

## Funding rounds

- Series B, Apr 11, 2024, $24M — Mayo Clinic Ventures, Canaan Partners, New Leaf Venture Partners, Correlation Ventures, Aberdeen Investments
- Series A, Aug 13, 2019, $8.2M — Mayo Clinic Ventures, Canaan Partners, New Leaf Venture Partners, Correlation Ventures

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A, Series B
- Aberdeen Investments (https://capitalatlas.ai/funds/aberdeen-investments) — Series B